Literature DB >> 28428349

Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.

Alicia García-Culebras1, Sara Palma-Tortosa1, Ana Moraga1, Isaac García-Yébenes1, Violeta Durán-Laforet1, Maria I Cuartero1, Juan de la Parra1, Ana L Barrios-Muñoz1, Jaime Díaz-Guzmán1, Jesús M Pradillo1, María A Moro1, Ignacio Lizasoain2.   

Abstract

BACKGROUND AND
PURPOSE: Hemorrhagic transformation is the main complication of revascularization therapies after stroke. Toll-like receptor 4 (TLR4) is implicated in cerebral damage and inflammation in stroke. This study was designed to determine the role of TLR4 in hemorrhagic transformation development after tissue plasminogen activator (tPA) administration.
METHODS: Mice expressing (TLR4+/+) or lacking functional TLR4 (TLR4-/-) were subjected to middle cerebral artery occlusion using an in situ thromboembolic model by thrombin injection into the middle cerebral artery, and tPA (10 mg/kg) was administered 20 minutes or 3 hours after ischemia. Infarct size, hemorrhages, IgG extravasation, matrix metalloproteinase 9 expression, and neutrophil infiltration were assessed 24 hours after ischemia.
RESULTS: In TLR4+/+, early reperfusion (tPA at 20 minutes) resulted infarct volume, whereas late recanalization (tPA at 3 hours) did not modify lesion size and increased the rate of the most severe hemorrhages. In TLR4-/- mice, both early and late reperfusion did not modify lesion size. Importantly, late tPA administration did not result in worse hemorrhages and in an increased bleeding area as occurred in TLR4+/+ group. In TLR4-/- animals, late reperfusion produced a lesser increase in matrix metalloproteinase 9 expression when compared with TLR4+/+ animals.
CONCLUSIONS: Our results demonstrate TLR4 involvement in hemorrhagic transformation induced by delayed tPA administration, very likely by increasing matrix metalloproteinase 9 expression.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  blood–brain barrier; hemorrhage; inflammation; middle cerebral artery; stroke

Mesh:

Substances:

Year:  2017        PMID: 28428349     DOI: 10.1161/STROKEAHA.116.015956

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  14 in total

1.  NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia.

Authors:  Chun-Chun Wei; Yuan-Yuan Kong; Xia Hua; Guo-Qiang Li; Si-Li Zheng; Ming-He Cheng; Pei Wang; Chao-Yu Miao
Journal:  Br J Pharmacol       Date:  2017-09-06       Impact factor: 8.739

Review 2.  Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.

Authors:  Chengli Liu; Jie Xie; Shanshan Sun; Hui Li; Tianyu Li; Chao Jiang; Xuemei Chen; Junmin Wang; Anh Le; Jiarui Wang; Zhanfei Li; Jian Wang; Wei Wang
Journal:  Cell Mol Neurobiol       Date:  2020-10-30       Impact factor: 5.046

3.  C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.

Authors:  Saif Ahmad; Chirayu Pandya; Adam Kindelin; Kanchan Bhatia; Rafay Chaudhary; Alok Kumar Dwivedi; Jennifer M Eschbacher; Qiang Liu; Michael F Waters; Md Nasrul Hoda; Andrew F Ducruet
Journal:  Br J Pharmacol       Date:  2020-03-04       Impact factor: 8.739

4.  Extension of Tissue Plasminogen Activator Treatment Window by Granulocyte-Colony Stimulating Factor in a Thromboembolic Rat Model of Stroke.

Authors:  Ike C Dela Peña; Samuel Yang; Guofang Shen; Hsiao Fang Liang; Sara Solak; Cesar V Borlongan
Journal:  Int J Mol Sci       Date:  2018-05-31       Impact factor: 5.923

5.  Microglial TLR4-dependent autophagy induces ischemic white matter damage via STAT1/6 pathway.

Authors:  Chuan Qin; Qian Liu; Zi-Wei Hu; Luo-Qi Zhou; Ke Shang; Dale B Bosco; Long-Jun Wu; Dai-Shi Tian; Wei Wang
Journal:  Theranostics       Date:  2018-10-29       Impact factor: 11.556

6.  Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke.

Authors:  Munehisa Shimamura; Hironori Nakagami; Hideo Shimizu; Hideyuki Mukai; Ryosuke Watanabe; Takeshi Okuzono; Tomohiro Kawano; Yuka Ikeda; Hiroki Hayashi; Shota Yoshida; Nan Ju; Hideki Mochizuki; Ryuichi Morishita
Journal:  Sci Rep       Date:  2018-12-11       Impact factor: 4.379

7.  LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.

Authors:  Be'eri Niego; Brad R S Broughton; Heidi Ho; Christopher G Sobey; Robert L Medcalf
Journal:  Fluids Barriers CNS       Date:  2017-11-21

Review 8.  Paradigm Shift to Neuroimmunomodulation for Translational Neuroprotection in Stroke.

Authors:  Diana Amantea; Rosaria Greco; Giuseppe Micieli; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

9.  Identification of Predictors for Hemorrhagic Transformation in Patients with Acute Ischemic Stroke After Endovascular Therapy Using the Decision Tree Model.

Authors:  Xin Feng; Gengfan Ye; Ruoyao Cao; Peng Qi; Jun Lu; Juan Chen; Daming Wang
Journal:  Clin Interv Aging       Date:  2020-09-08       Impact factor: 4.458

10.  Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.

Authors:  Dong-Ling Liu; Zhi Hong; Jing-Ying Li; Yu-Xin Yang; Chu Chen; Jun-Rong Du
Journal:  J Neuroinflammation       Date:  2021-06-24       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.